Skip Nav Destination
Issues
Introduction
Articles
Characterization and Significance of Sulfonylurea Receptors
Diabetes Care August 1990, Vol.13, 2-8. doi:https://doi.org/10.2337/diacare.13.3.2
Mechanisms of Sulfonylurea-lnduced Insulin Release
Diabetes Care August 1990, Vol.13, 9-17. doi:https://doi.org/10.2337/diacare.13.3.9
Sulfonylureas Why, Which, and How?
Diabetes Care August 1990, Vol.13, 18-25. doi:https://doi.org/10.2337/diacare.13.3.18
Acute Actions of Sulfonylurea Drugs During Long-Term Treatment of NIDDM
Ole K Faber, MD, PhD; H Beck-Nielsen, MD, PhD; C Binder, MD, PhD; P Butzer, MD; EM Damsgaard, MD; F Froland, MD, PhD; E Hjollund, MD; HO Lindskov, MD; A Melander, MD, PhD; O Pedersen, MD, PhD; P Petersen, MD; N Schwarts Sorensen, MD, PhD; E Wåhlin-Boll, PhD
Diabetes Care August 1990, Vol.13, 26-31. doi:https://doi.org/10.2337/diacare.13.3.26
Effect of Acarbose on Carbohydrate and Lipid Metabolism in NIDDM Patients Poorly Controlled by Sulfonylureas
Gerald M Reaven, MD; Claude K Lardinois, MD; Michael S Greenfield, MD; Herbert C Schwartz, MD; Hendrick J Vreman, PhD
Diabetes Care August 1990, Vol.13, 32-36. doi:https://doi.org/10.2337/diacare.13.3.32
Metabolic Effects of Combination Glipizide and Human Proinsulin Treatment in NIDDM
Diabetes Care August 1990, Vol.13, 42-46. doi:https://doi.org/10.2337/diacare.13.3.42
Combined Insulin-Sulfonylurea Therapy in Treatment of NIDDM
Diabetes Care August 1990, Vol.13, 47-52. doi:https://doi.org/10.2337/diacare.13.3.47
Will Sulfonylurea Treatment of Impaired Glucose Tolerance Delay Development and Complications of NIDDM?
Arne Melander, MD, PhD; Per-Olof Bitzén, MD, PhD; Gunnar Sartor, MD, PhD; Bengt Scherstén, MD, PhD; Elisabeth Wåhlin-Boll, PhD
Diabetes Care August 1990, Vol.13, 53-58. doi:https://doi.org/10.2337/diacare.13.3.53
